Elotuzumab is used in combination chemotherapy to treat multiple myeloma (bone marrow cancer). Elotuzumab is given together with lenalidomide or pomalidomide, and a steroid medicine called dexamethasone. Elotuzumab may also be used for purposes not listed in this medication guide.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Elotuzumab for injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Elotuzumab for injection medicine cost price in India.
The order for Elotuzumab for injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Trade Name: On Request
Generic Name: Elotuzumab
For Injection: 300 mg or 400 mg lyophilized powder in a single-dose vial for reconstitution.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Elotuzumab for injection on prescription and Import License in Patient's Name only.
For overseas patients, Elotuzumab for injection can be made available in Send your enquiry to find Elotuzumab for injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma For More Details
Elotuzumab Triplet Approved by FDA for Treatment of Myeloma For More Details
European Commission Approves (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma For More Details